<p>/PRNewswire/ -- Schall 律师事务所是一家全国性的股东权益诉讼事务所，宣布正在调查 Oculis Holding AG（&#34;Oculis&#34;或&#34;公司&#34;）（NASDAQ: OCS）投资者的索赔，因其违反证券法。</p>
<p>调查的重点是公司是否发布了虚假和/或误导性声明，和/或未能披露对投资者相关的信息。Oculis 声称其第三阶段 DIAMOND 试验正在&#34;按计划推进&#34;，但随后在 2026 年 5 月 29 日宣布，两个 DIAMOND 试验未能达到其主要终点。公司补充说，基于这些结果，它将不再寻求对其药物候选者进行 FDA 申请。</p>
<p>如果您是遭受损失的股东，请点击此处参与。</p>
<p>我们还鼓励您联系 Schall 律师事务所的 Brian Schall，地址：2049 Century Park East, Suite 2460, Los Angeles, CA 90067，电话：310-301-3335，免费讨论您的权利。您也可以通过事务所的网站 www.schallfirm.com 或电子邮件 [email protected] 与我们联系。</p>
<p>Schall 律师事务所代表全球投资者，专注于证券集体诉讼和股东权益诉讼。</p>
<p>在某些司法管辖区，根据适用法律和伦理规则，本新闻稿可能被视为律师广告。</p>
<p><strong>联系方式：</strong></p>
<p>Schall 律师事务所</p>
<p>Brian Schall, Esq.</p>
<p>310-301-3335</p>
<p>[email protected]</p>
<p>www.schallfirm.com</p>
<p>来源：Schall 律师事务所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjA4Jk5ld3NJdGVtSWQ9TEE3NzgyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDgxMjQzUFJfTkVXU19VU1BSX19fX19MQTc3ODI2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjA4Jk5ld3NJdGVtSWQ9TEE3NzgyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDgxMjQzUFJfTkVXU19VU1BSX19fX19MQTc3ODI2"/></p>

<p>Schall 律师事务所正在调查 Oculis Holding AG（纳斯达克代码：OCS）是否存在潜在的证券法违规行为。调查的重点是该公司是否通过声称其第三阶段 DIAMOND 试验按计划推进而发布了误导性声明，然而在 2026 年 5 月 29 日却宣布试验失败并停止 FDA 申请计划。遭受损失的投资者被鼓励联系该事务所以讨论他们的权利</p>

<p>, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Oculis Holding AG (&#34;Oculis&#34; or &#34;the Company&#34;) (NASDAQ: OCS) for violations of the securities laws.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Schall 律师事务所是一家全国性的股东权益诉讼事务所，宣布正在调查 Oculis Holding AG（&#34;Oculis&#34;或&#34;公司&#34;）（NASDAQ: OCS）投资者的索赔，因其违反证券法。</p>
</div><p>The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Oculis claimed that its Phase 3 DIAMOND trials were &#34;advancing as planned,&#34; but then announced on May 29, 2026, that both DIAMOND trials failed to meet their primary endpoints. The Company added that based on these results, it would not pursue an FDA filing for its drug candidate.</p>
<div class="lb-trans"><p>调查的重点是公司是否发布了虚假和/或误导性声明，和/或未能披露对投资者相关的信息。Oculis 声称其第三阶段 DIAMOND 试验正在&#34;按计划推进&#34;，但随后在 2026 年 5 月 29 日宣布，两个 DIAMOND 试验未能达到其主要终点。公司补充说，基于这些结果，它将不再寻求对其药物候选者进行 FDA 申请。</p>
</div><p>If you are a shareholder who suffered a loss, click here to participate.</p>
<div class="lb-trans"><p>如果您是遭受损失的股东，请点击此处参与。</p>
</div><p>We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].</p>
<div class="lb-trans"><p>我们还鼓励您联系 Schall 律师事务所的 Brian Schall，地址：2049 Century Park East, Suite 2460, Los Angeles, CA 90067，电话：310-301-3335，免费讨论您的权利。您也可以通过事务所的网站 www.schallfirm.com 或电子邮件 [email protected] 与我们联系。</p>
</div><p>The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.</p>
<div class="lb-trans"><p>Schall 律师事务所代表全球投资者，专注于证券集体诉讼和股东权益诉讼。</p>
</div><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.</p>
<div class="lb-trans"><p>在某些司法管辖区，根据适用法律和伦理规则，本新闻稿可能被视为律师广告。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>联系方式：</strong></p>
</div><p>The Schall Law Firm</p>
<div class="lb-trans"><p>Schall 律师事务所</p>
</div><p>Brian Schall, Esq.</p>
<div class="lb-trans"><p>Brian Schall, Esq.</p>
</div><p>310-301-3335</p>
<div class="lb-trans"><p>310-301-3335</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.schallfirm.com</p>
<div class="lb-trans"><p>www.schallfirm.com</p>
</div><p>SOURCE The Schall Law Firm</p>
<div class="lb-trans"><p>来源：Schall 律师事务所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNjA4Jk5ld3NJdGVtSWQ9TEE3NzgyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjA2MDgxMjQzUFJfTkVXU19VU1BSX19fX19MQTc3ODI2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA77826&amp;Transmission_Id=202606081243PR_NEWS_USPR_____LA77826&amp;DateId=20260608"/></p>

ETOCS 的投资者有机会与 Schall 律师事务所合作，参与对 Oculis Holding AG 的欺诈调查